- Home
- CPA vs KNSA Comparison
CPA vs KNSA Comparison
Compare CPA & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPA | KNSA |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | Panama | United Kingdom |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 4.9B |
| IPO Year | 2005 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CPA | KNSA |
|---|---|---|
| Price | $132.02 | $78.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | ★ $159.40 | $60.86 |
| AVG Volume (30 Days) | 228.9K | ★ 415.4K |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | ★ 6.09% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $15.51 | $37.48 |
| Revenue Next Year | $7.25 | $17.87 |
| P/E Ratio | ★ $9.05 | $293.81 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $107.44 | $35.33 |
| 52 Week High | $160.47 | $82.94 |
Technical Indicators
Market Signals| Indicator | CPA | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 54.16 |
| Support Level | $126.04 | $44.95 |
| Resistance Level | $135.96 | $81.97 |
| Average True Range (ATR) | 2.84 | 2.39 |
| MACD | 0.65 | -0.39 |
| Stochastic Oscillator | 88.02 | 56.80 |
Price Performance
Historical ComparisonAbout CPA Copa Holdings S.A.
Copa Holdings SA is a provider of airline passenger and cargo services through its subsidiaries. The company operates through the air transportation segment. It offers international air transportation for passengers, cargo, and mail, operating from its Panama City hub in the Republic of Panama, and domestic and international air transportation for passengers, cargo, and mail with a point-to-point route network through Copa Colombia, a Colombian air carrier. The company's geographical segments are North America, South America, Central America, and the Caribbean. It derives the maximum revenue from North America.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.